So far we do not have an ASH selloff, which is nice to see. I think in general we remain with some seasonal and broader market tailwinds and that should take us through JPM in January. In fact, we are probably getting close to the M&A speculation time but remember that last year was actually […]
December 3rd Biotech (and MLP) Update
Sorry for the delay but we are dealing with kids that were exposed to COVID and having to get them tested and now they are back in virtual school. I am sure many of you have dealt with similar (or worse) issues and thankfully for us it is just added time but it certainly has […]
December 1st Biotech Update
A strong start to the week that is continuing. While certain sentiment measures are getting into danger territory, it still seems like the market has a little bit more room for running. The uncertainty around the elections is waning and the Biden economic team seems to indicate a strong desire for fiscal stimulus. We are […]
November 30th Biotech Update
As I have said there will be a tug of war in the market and so far vaccine hopes and seasonality are winning over the growing pandemic. One really has to worry about an out of control pandemic combined with a holiday season but the market is not quite ready to worry about it. I […]
November 23 Biotech Update
The market dynamics remain the same. We are entering what tends to be a seasonally positive period of the year, which might add some tailwind to the broader market. While I still think the market is going to focus on the prospects of the vaccine coming next year as opposed to the out of control […]
APLIF – Appili Therapeutics and Avigan the Antiviral Pill to Treat Coronavirus
Canada TSX: APLI, US OTC: APLIF Recent vaccine news from Pfizer (PFE) and Moderna (MRNA) provide some optimism to a world suffering from disease, death, and lockdown, and desperately looking for a solution to the COVID-19 pandemic for a return to normal life and work. Safe and effective vaccines will help contain the spread of […]
November 20th Biotech Update
I think choppy might have been the best description of the market at this point. This makes sense give the competing influences on both the market and economy. I would not be surprised to see this chop continue or perhaps even see some consolidation. The broader market seems in a little more precarious position than […]
November 19th Biotech Update
Nothing crazy happening in the market at this point. I do not see anything that compelling low or high and I think the market continues to struggle with the hope of the vaccines versus the pain of an out of control spread. There is likely a point where the immediate term gets so bad that […]
November 18th Biotech (and MLP) Update
So the market continues to look good including the sector that is pushing all time highs. While I often say the trend is your friend (and it is), it might also be time to pull out another saying. When markets are making all time highs, the most likely outcome is to continue to make marginal […]
Pluristem- Expectation Ahead of CLI Phase-3 Interim Results
These are the questions that many are asking me these days regarding PSTI: * When will the interim Ph3 data be released? * What is taking them so long? * Is there a chance they are withholding the data because it is negative, and they will wait until full study data is available to provide […]
November 16th Biotech Update
Another start to the week with some more vaccine announcements (positive). It was good to see more positive vaccine data but it does not change the dynamic that I see with the market. There appears to be a real light at the end of the tunnel but the path to the end will be very […]
November 13th Biotech Update
So its been a decent week and hopefully we can end on a strong note. Not a lot of news to move the market or sector and perhaps that means we get a decent look at the underlying sentiment of the market. We are past the major catalysts of November and there is really not […]
November 12th Biotech Update
The market continues to move along it sort of the honeymoon period post election risk reduction. I still worry about the pandemic as cases continue to grow unabated in the EU and US. Is it possible that the market (and Americans) simply do not care about it anymore and have simply accepted the death as […]
November 11th Biotech Update
Below are my comments on the guidelines that you can forward along. So it looks like the market has digested the outcome of the election for the most part. I still think there is going to be a tug of war in terms of COVID with the vaccine news pushing the post-COVID names but […]
November 9th Biotech Update
We do not have merger Monday, so I suspect the market will be disappointed. I joke of course as this is going to be a massive relief rally on the news of the PFE vaccine. While there will certainly be a rally that raises almost everyone, there will likely be rotations out of COVID treatment […]
SRPT – The Street Will Get It – Study-103 Is the Fast Path to Full Approval
Last week, Sarepta Therapeutics ( SRPT) on the 3Q earnings call provided key updates on SRP-9001 gene therapy in Duchenne Muscular Dystrophy (DMD). Where they already met the FDA and resolved the FDA’s requests with regard to the potency assays for the commercial material to be used in the next studies, and they came with […]
November 6th Biotech Update
It seems like the election is all but over. The votes have turned and clearly point to a Bide victory and as of writing speculation is that Trump will admit defeat. Of course, Trump does not have to concede for Biden to win but it would assuage investors and remove the last bit of risk […]
November 5th Biotech Update
While we clearly do not have a clear winner from the election, it at least looks like the market has decided where the election is going. If there was uncertainty over the outcome, then the market would not have rallied and volatility would not have dropped. Given the pace of vote counting, it looks like […]
November 4th Biotech Update
The election is (sort of) over. While it ended up being closer than the polls indicated, it appears that Biden will win barring some unprecedented court decision to invalidate large numbers of legally cast votes. The closeness of the election, however, makes the Senate now lean Republican. I suspect both Georgia contests will have to […]
November 2nd Biotech Update
This is the literal calm before the storm. The election is tomorrow and the adu AdCom is Friday. Plus, we still have a number earnings coming this week as well. Even with all of that news the week starts off with basically nothing that meaningful so there is not much to say. That is not […]
